Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Study Identifier
214868-004
CT.gov Identifier
NCT01157377
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • AGN-214868
  • AGN-214868 placebo
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18 - 75 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * If female, must be of nonreproductive potential * If male, must agree to use acceptable contraception * Symptoms of overactive bladder with urinary urgency incontinence * Inadequate response or limiting side effects with anticholinergics for the treatment of OAB
    Exclusion Criteria:
    * Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple sclerosis) * History of bladder surgery * Treatment with botulinum toxin therapy of any serotype for any non-urological condition within the prior 12 weeks * Previous treatment with botulinum toxin therapy of any serotype for any urological condition

    Protocol Summary

    This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.

    Study Locations

    Location
    Status
    Location
    Richmond, Virginia, United States
    Status
    Not applicable
    Location
    Lyon, France
    Status
    Not applicable
    Location
    Amsterdam, Netherlands
    Status
    Not applicable